Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × rrCLL × pembrolizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 446 Melanoma 285 Squamous Cell Carcinoma of Head and Neck 227 Parkinson Disease 4, Autosomal Dominant Lewy Body 187 Neoplasms 176 Breast Neoplasms 161 Triple Negative Breast Neoplasms 160 Neoplasm Metastasis 154 Lung Neoplasms 140 Colorectal Neoplasms 139 Carcinoma, Renal Cell 129 Head and Neck Neoplasms 118 Stomach Neoplasms 101 Ovarian Neoplasms 97 Carcinoma, Transitional Cell 90 Pancreatic Neoplasms 80 Urinary Bladder Neoplasms 79 Carcinoma, Hepatocellular 73 Endometrial Neoplasms 70 Uterine Cervical Neoplasms 64 Esophageal Neoplasms 58 Recurrence 50 Prostatic Neoplasms 48 Sarcoma 43 Carcinoma 41 Small Cell Lung Carcinoma 38 Carcinoma, Squamous Cell 38 Glioblastoma 37 Hodgkin Disease 35 Lymphoma 33

Interventions

pembrolizumab 1 dinaciclib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02684617 2021-03-01

KEYNOTE-155

Merck Sharp & Dohme LLC

Phase 1 Terminated

75 enrolled 17 charts

rrCLL

Data powered by HemOnc (CC BY 4.0) Colophon ⚡